Factors Affecting Mortality and Morbidity of Patients With Cirrhosis Hospitalized for Spontaneous Bacterial Peritonitis
|
|
- Estella Park
- 5 years ago
- Views:
Transcription
1 POSter PreSentAtIOn Factors Affecting Mortality and Morbidity of Patients With Cirrhosis Hospitalized for Spontaneous Bacterial Peritonitis Fatih Ensaroğlu, 1 Murat Korkmaz, 1 Ali Ümit Geçkil, 2 Serkan Öcal, 1 Bengisu Koç, 3 Özgün Yıldız, 3 Fatma Büşra Atalay, 3 Emine Gül Taş, 3 Mehmet Haberal 4 Abstract Objectives: Spontaneous bacterial peritonitis, unless originating from surgery or an intra-abdominal source, is an infection diagnosed by neutrophil counts greater than 250/mm 3 in ascites. Spontaneous bacterial peritonitis is the most common infection among patients hospitalized with cirrhosis, with a prevalence of 9% and a risk of development among all patients with cirrhosis within 1 year of 10%. No valid parameters have been defined to predict the mortality related to spontaneous bacterial peritonitis. Unless it is treated, the mortality rate as a result of spontaneous bacterial peritonitis is 50%, and serious complications may arise. Materials and Methods: Medical records from 29 patients on the deceased-donor transplant waiting list and receiving treatment at the Başkent University Hospital Gastroenterology Clinic for cirrhotic ascites infection between 1996 and 2013 were analyzed. Demographic information, para - centesis findings, clinical follow-up, and treatment results were reviewed and collected from patient medical records, with data recorded to the research form. Results: In our patient group, 72.4% were men and the average age was 46.6 years. Most of our patients were at advanced stage, with 55.2% having From the 1 Department of Gastroenterology, Baskent University Faculty of Medicine; the 2 Department of Family Medicine, Baskent University Faculty of Medicine; the 3 Baskent University Faculty of Medicine; and the 4 Department of General Surgery, Baskent University Faculty of Medicine, Ankara, Turkey Acknowledgements: The authors declare that they have no sources of funding for this study, and they have no conflicts of interest to declare. Corresponding author: Fatih Ensaroğlu, Department of Gastroenterology, Baskent University Faculty of Medicine, Fevzi Çakmak Cad, Ankara 06490, Turkey Phone: Fax: fatihensaroglu@gmail.com Experimental and Clinical Transplantation (2015) Suppl 3: a Child-Pugh score of C and an average Model for End-Stage Liver Disease score of 17 ± 4.1. We found that 34.5% of the patients received prophylactic treatment for spontaneous bacterial peritonitis, 72.4% received a proton pump inhibitor, and 82.8% had treatment with intravenous albumin support at the time of diagnosis. Albumin treatment showed no effect on mortality. Mortality rate among patients with Child-Pugh score of C was 81.3%. Conclusions: Existence of chronic renal failure, liver graft surgery, and hepatocellular cancer did not seem to have a significant effect on patient mortality. The albumin treatment protocol showed no significant difference despite common belief among physicians. Key words: Ascites, Albumin treatment, Liver graft surgery, Child-Pugh score Introduction Spontaneous bacterial peritonitis (SBP) is an infection diagnosed by a neutrophil count of greater than 250 neutrophils/μl3 in ascites unless it originates from surgery or an intra-abdominal source. 1 No valid parameters to predict SBP-related mortality have been identified. 2 However, if not treated, SBP can be fatal in 50% of patients and serious complications may arise. Spontaneous bacterial peritonitis is a common bacterial infection among patients with cirrhosis, with a prevalence of 10% to 30% in hospitalized patients and 1.5% to 3.5% in patients who are not hospitalized. 3 Spontaneous bacterial peritonitis is one of the leading causes of mortality and morbidity. 4 All patients with cirrhosis and ascites are at risk of developing SBP. One-year mortality after first diagnosis of SBP is shown to be between 31% and 93%. 5 However, early diagnosis and early Copyright Başkent University 2015 Printed in Turkey. All Rights Reserved. DOI: /ect.tdtd2015.P71
2 132 Fatih Ensaroğlu et al/experimental and Clinical Transplantation (2015) Suppl 3: Exp Clin Transplant antibiotic treatment has decreased this rate to 20% to 30% in recent years. 1,5 Spontaneous bacterial peritonitis is a mono - microbial infection of ascites, which may occur by infection, translocation, or hematogenous dissemination of intestinal flora. 4 Bacterial trans location is the major mechanism of SBP. 3 Moreover, excess bacterial production in the intestine triggers trans - location. 4 The frequency of ascites development in patients with compensated cirrhosis in a 5-year span is about 30%. Prognosis of patients with cirrhosis significantly worsens after ascites development. Although the 1-year survival rate in patients with compensated cirrhosis is above 90%, the rate decreases to 50% in decompensated patients. After ascites development, 10% to 30% of patients develop SBP within 1 year. Patients who had 1 SBP attack and survived are at risk of relapsing within 1 year. 6 About 83% to 93% of patients recover from their first SBP occurrence when treated with cefotaxime, a third-generation cephalosporin. Mortality of patients treated in a hospital setting with cefotaxime was found to be 29%, a consistent rate in many other studies. 4-6 However, for patients treated in the hospital setting with both cefotaxime and albumin, the mortality decreased to 10%. Albumin may decrease the risk of hepatorenal syndrome development, a serious complication, 6 by increasing the effective circulating blood volume. Serum albumin concentration is responsible for 75% of plasma osmotic pressure. As a result, plasma is used for volume replacement. Moreover, albumin is a multifunctional protein that plays a role in anti - oxidation, immunomodulation, and detoxification. Liver damage, which prevents albumin to act as an immunomodulator, is 1 factor leading to SBP development. Hemodynamic disorders and multiorgan failure may occur as a result of hypo - albuminemia. Studies show that albumin infusion given to patients with SBP during antibiotic treatment decreases renal failure incidence and mortality. 7 In a study by Cho and associates, 8 patients with SBP were given intravenous albumin treatment (1.5 g/kg/d). This treatment resulted in patients not needing the withdrawal of large amounts of fluid (> 5 L) during paracenteses. 8 The production of C-reactive protein (CRP) in the body is affected by liver function; however, its clinical importance among patients with cirrhosis has not been clarified. In a study showing the relation between serum CRP levels and efficiency of treatment among 182 patients, 54.2% of the patients who died from SBP had responded to antibiotic therapy. It is also shown that high CRP levels cause low response to antibiotic therapy. 8 The use of prophylactic treatment in patients with ascites and SBP is an important issue. Only patients at high risk for development of SBP should receive prophylactic treatment because the long-term use of antibiotics for prophylactic use can cause resistance to bacterial emergence. 9 Pathogens responsible for SBP are usually gramnegative bacteria that have translocated from the intestines. These pathogens include Escherichia coli, Klebsiella pneumonia, and Streptococcus pneumonia. As a result, norfloxacin and trimethoprim-sulfa - methoxazole are appropriate for prophylaxis. 9 Most centers, including ours, prefer norfloxacin as firstline treatment. Bacterial overgrowth and decreased small intestine motility are more common among patients with SBP than in those without the disease. Bacterial colonization is much easier because the immune systems of patients with SBP are weaker. 10 Proton pump inhibitors and H2 receptor antagonists are drugs used to suppress gastric acid. Treatment of patients with cirrhosis with acid suppressors can cause bacterial overgrowth and translocation. Risk of SBP development in patients with cirrhosis who are not being treated with proton pump inhibitors is 3 times more likely than in those who are receiving this treatment. 11 Although some studies have reported that the risk is not increased, 10 indications for proton pump inhibitors have to be questioned first. When to start and whether long-term use is appropriate require careful consideration. 11 In this study, we aimed to outline our experiences with SBP in patients with cirrhosis. Materials and Methods We reviewed the hospital registry database of patients with cirrhotic ascites infection who had received inpatient treatment at the Başkent University Hospital Gastroenterology Clinic between 1995 and The following data were collected: demographics; cause of cirrhosis (hepatitis B virus, hepatitis C virus, alcohol, metabolic, vascular, cryptogenic); reason for hospital admission
3 Fatih Ensaroğlu et al/experimental and Clinical Transplantation (2015) Suppl 3: (shortness of breath, renal failure, decompensated ascites, abdominal distension, fever, stomach ache, change in cognitive status, asymptomatic, coincidence); examination findings (blood pressure, pulse, body temperature, respiration, abdominal sensitivity, rebound sensitivity, encephalopathy); existence of systemic disease and hepatocellular carcinoma; Child-Pugh and Model for End-Stage Liver Disease scores; serum values (prothrombin time, leukocyte count, total protein, international normalized ratio, and serum albumin, serum urea nitrogen, creatinine, and sodium levels); serum ascites albumin gradient; CRP levels (before and after treatment); paracentesis findings (ascites protein, ascites albumin, ascites leukocyte level, ascites neutrophil level, culture); diagnosis time of cirrhosis and SBP; treatment; existence of control paracentesis after treatment; existence of complications during therapy; intensive care admission history; status of prophylaxis; whether albumin was given; use of proton pump inhibitor; and time of death or whether death did not occur. Exclusion criteria were presence of chronic renal failure, secondary peritonitis, patients who were on peritoneal dialysis, and missing information. Patients were reviewed retrospectively. The study was approved by the ethics committee, and all protocols conformed with the ethical guidelines of the 1975 Helsinki Declaration. Patients provided written informed consent to be included on the registry. Statistical analyses were performed with SPSS software (SPSS: An IBM Company, version 17.0, IBM Corporation, Armonk, NY, USA). Continuous variables are presented as average ± SD (or median and range from minimum to maximum), whereas categorical variables are presented as numbers and percentage. The ratios of patient mortality, cause of cirrhosis, history of liver transplant surgery, existence of hepatocellular carcinoma, Child-Pugh score, Model for End-Stage Liver Disease score, use of albumin replacement, use of proton pump inhibitors and cephalosporin treatment, and whether patients received prophylactic treatment were compared within each other using chi-square test. Wilcoxon rank sum test was used to compare CRP levels before and after treatment and paracentesis findings (the presence of proteins, albumin, leukocytes, neutrophils, culture). P <.05 was considered statistically significant in all analyses. Results In our study, 40 of 351 patients with cirrhosis (11.3%) at the Gastroenterology Clinic at Başkent University Hospital developed SBP. After application of exclusion and inclusion criteria, 29 patients were included in our study. General characteristics of patients and reasons for hospital admission are listed in Tables 1 and 2. The demographic traits and admission reasons of most of the patients in our study. The patient examination results and laboratory findings are listed in Tables 3 and 4. Hepatitis B virus was the leading cause of cirrhosis (34.5% of patients), with hepatitis C virus as the second leading cause (24.1% of patients) (Table 1). Cirrhosis from alcohol use was found in 13.8% of our study patients (Table 1). table 1. Patient Characteristics Characteristic Number or Percent of Patients (N = 29) Age at cirrhosis diagnosis (y) ± Age at development of spontaneous bacterial peritonitis diagnosis (y) ± Sex (male) 72.4% Cause of cirrhosis Hepatitis B virus 34.5% Hepatitis C virus 24.1% Hepatitis B virus and hepatitis D virus 0% Alcohol 13.8% Metabolic 17.2% Cryptogenic 34.5% Existence of another disease Hepatocellular carcinoma 27.6% Liver transplant 20.7% Child-Pugh score Class A 6.9% Class B 37.9% Class C 55.2% Model for End-Stage Liver Disease score 17 ± 4.1 Results are shown as means ± SD or percent. table 2. Reason for Hospital Admission Reason for Hospital Admission Percent of Patients (N = 29) Bleeding 13.8 Shortness of breath 34.5 Renal failure 10.3 Ascites 34.5 Abdominal distension 55.2 Fever 37.9 Stomach ache 41.4 Cognitive change 34.5 No symptoms 34.5 Diagnosis of SBP by culture-positive variant occurred in 17% of patients, with the diagnosis by neutrophil count occurring in 83% of patients (mean neutrophil count of 560/μL). The antibiotic regimens included third-generation cephalosporin (24% of patients), other antibiotic regimens (45% of patients),
4 134 Fatih Ensaroğlu et al/experimental and Clinical Transplantation (2015) Suppl 3: Exp Clin Transplant table 3. Patient Examination Results Test Number or Percent of Patients (N = 29) Systolic blood pressure (mm Hg) ± Diastolic blood pressure (mm Hg) ± Pulse (beats/min) ± 16.6 Body temperature ( C) ± 0.9 Respiration (breaths/min) ± Abdominal sensitivity 51.7% Rebound 20.7% Encephalopathy 51.7% Results are shown as average ± SD or percent. table 4. Patient Laboratory Results Laboratory Test in Serum Average ± SD (N = 29 Patients) PT (seconds) ± 7.1 INR 1.72 ± 0.99 Leukocyte (count/µl) 7.58 ± 3.71 Total protein (g/dl) 5.91 ± 1.25 Albumin (g/l) 25.5 ± 6.7 Total bilirubin (µmol/l) 4.83 ± 5.95 Serum urea nitrogen (mmol/l) 29.7 ± 17.7 Creatinine (mg/dl) 1.24 ± 1.3 Sodium (mmol/l) ± 6.9 Ascites albumin gradient (mg/dl) 2.15 ± 0.63 C-reactive protein before treatment (nmol/l) ± C-reactive protein after treatment (nmol/l) ± Abbreviations: INR, international normalized ratio; PT, prothrombin time and a combination of third-generation cephalosporin plus other antibiotics (31% of patients). In the 29 patients, 6.9% of patients were scored as Child-Pugh Class A, 37.9% as Child-Pugh Class B, and 55.2% as Child-Pugh Class C, with the high number with C score because patients presented with poor medical conditions. In our study, there was no mortality among patients with Child-Pugh Class A. However, the mortality rate was 81.3% for those with Child-Pugh Class C. In our study group, average Model for End-Stage Liver Disease score was 17 ± 4.1. Review of patient medical records showed a 1-year mortality rate of 44.83%. We found no significant correlation in terms of mortality between patients receiving proton pump inhibitors, thirdgeneration cephalosporin, albumin infusion, or thirdgeneration cephalosporins plus albumin infusion treatment. Discussion According to the literature, after development of SBP, 29% of the patients die within 1 year. 1 Spontaneous bacterial peritonitis is a complication that is life threatening and seen in cirrhotic progress. According to the literature, 8% to 27% of patients admitted with ascites to a hospital have SBP. 12 Hepatitis B virus, hepatitis C virus, hepatitis B and hepatitis D virus, alcohol-related, metabolic, and cryptogenic reasons are among the causes of cirrhosis. Although 1 study has stated that alcohol is the primary reason, another study has claimed hepatitis B virus as the principle cause of cirrhosis. 6,12 These differences may be related to the geographic region where the studies were performed. Although alcohol remains in the foreground versus viral hepatitis in Western Europe and the United States, hepatitis B virus remains the primary reason in Turkey and in other Eastern communities. In our study, the patients presented with advanced stages of cirrhosis and 20.7% had received a liver transplant, with death occurring in 66.7% of patients receiving a transplant. This high rate can be explained by the poor conditions of patients. In a previous study of 40 patients who had developed SBP, 25.7% were score as Child-Pugh Class B and 74.3% with Child-Pugh Class C. In the same study, 27.5% of the patients later developed hepatocellular carcinoma, reflecting the poor condition of patients, similar to our study. 13 Measured levels of CRP at the beginning of treatment, existence of hepatocellular carcinoma, and Child-Pugh scores are independent risk factors for mortality for hospitalized patients. 8 In our study, patients had an average CRP level of 51.7 mg/dl before treatment. After treatment, this average level was nmol/l. We had expected a fall in CRP levels at the end of antibiotic treatment. Our findings were statistically significant and supported our expectations (P =.042). C-reactive protein levels increase in response to infection in patients with cirrhosis, although their liver s ability to synthesize decreases. A high CRP level indicates that the infection is more serious than initially predicted and may result in a less successful treatment. The prevalence of hepatocellular carcinoma is high among patients with cirrhosis and SBP. According to a previous study, hepatocellular carcinoma occurs in 41.5% of these patients.1 Moreover, in a similar study, 35 of 168 patients (20.8%) with cirrhosis and SBP were diagnosed with hepatocellular carcinoma. 9 In our study, hepato - cellular carcinoma was found in 27.6% of patients. Albumin increases the effective blood volume and blood flow in the splanchnic area; as a result, this avoids development of hepatorenal syndrome. Albumin administration to patients with serum
5 Fatih Ensaroğlu et al/experimental and Clinical Transplantation (2015) Suppl 3: albumin levels below 25 g/l can decrease the probability of developing hepatorenal syndrome. In our study, 82.8% of patients received albumin treatment. The mortality rate in patients who received albumin treatment was 66.7%, whereas this rate was 80% in those who did not receive this treatment. Therefore, albumin replacement treatment in patients with cirrhosis and SBP can decrease the mortality rate. In addition, a related study showed that mortality rate was 16% for patients who had albumin replacement treatment and 35.4% for those who did not have this treatment. 14 Standard treatment of SBP is third-generation cephalosporin (ceftriaxone), administered intra - venously at 1 to 2 grams, 3 times per day, for 5 days. Mortality for hospitalized patients treated with cefotaxime was shown to be 29%, which is similar to the rate shown in most studies on SBP. 9,10 However, the mortality rate for hospitalized patients treated with a combination of cefotaxime and albumin was 10%. 8 According to another study, the mortality rate for hospitalized patients treated with cefotaxime only was 41%; however, this rate was 22% in patients treated with both cefotaxime and albumin. 15 In our study, 24% of patients received treatment with cefotaxime, 45% received antibiotics, and 31% received both cefotaxime and other antibiotics. Patients who were treated with both cephalosporin and albumin had a mortality rate of 75%, whereas this rate was 64.7% in those who were not treated. Because most of our patients had advanced-stage cirrhosis, cephalosporin was given along with albumin. However, the mortality rate was higher than we expected. Prophylactic treatment is given to patients with cirrhosis and ascites who have not developed SBP but are at a high risk of advancing to SBP. Administration of 400 mg norfloxacin 1 time per day is recommended for these patients indefinitely to lower the risk of SBP. 9 In a recent study of norfloxacin in 35 patients with cirrhosis, 14 had infection (40%) and 2 had SBP (6%). This study showed the mortality rate for patients who took prophylaxis to be 29%; however, those who did not had a mortality rate of 39.4%. 16 In our study, 34.5% of patients received prophylactic treatment, with mortality rate in these patients of 70%. In contrast, the rate among patients who did receive prophylactic treatment was 68%. A high mortality rate despite prophylaxis can be generally attributed to the advanced stage of cirrhosis in our patients. In addition, because the numbers of quinolone-resistant bacteria increase in fecal flora of patients, the activity of norfloxacin decreases with time. 16 In a study of 184 patients, 30-day mortality rate was 27% in patients with a Model for End-Stage Liver Disease score of Our study also included patients in poor condition with correspondingly high Model for End-Stage Liver Disease scores. 2 A limitation of our study was the inability to include patients who met the inclusion criteria but had medical records that were inaccessible or had chronic renal failure. In conclusion, most of our patients were at advanced stage of cirrhosis, with treatment efficiency below our expectations. References 1. Tsung PC, Ryu SH, Cha IH, et al. Predictive factors that influence the survival rates in liver cirrhosis patients with spontaneous bacterial peritonitis. Clin Mol Hepatol. 2013;19(2): Tandon P, Kumar D, Seo YS, et al. The 22/11 risk prediction model: a validated model for predicting 30-day mortality in patients with cirrhosis and spontaneous bacterial peritonitis. Am J Gastroenterol. 2013;108(9): Joseph T, Sobhan P, Bahuleyan S, et al. Non-typhoidal salmonella: an unusual cause of spontaneous bacterial peritonitis in decompensated cirrhosis. Gastroenterol Rep (Oxf ). 2014;2(3): Sheikhbahaei S, Abdollahi A, Hafezi-Nejad N, Zare E. Patterns of antimicrobial resistance in the causative organisms of spontaneous bacterial peritonitis: a single centre, six-year experience of 1981 samples. Int J Hepatol. 2014;2014: Oladimeji AA, Temi AP, Adekunle AE, Taiwo RH, Ayokunle DS. Prevalence of spontaneous bacterial peritonitis in liver cirrhosis with ascites. Pan Afr Med J. 2013;15: Koulaouzidis A, Bhat S, Karagiannidis A, Tan WC, Linaker BD. Spontaneous bacterial peritonitis. Postgrad Med J. 2007;83(980): Garcia-Martinez R, Caraceni P, Bernardi M, Gines P, Arroyo V, Jalan R. Albumin: pathophysiologic basis of its role in the treatment of cirrhosis and its complications. Hepatology. 2013;58(5): Cho Y, Park SY, Lee JH, et al. High-sensitivity C-reactive protein level is an independent predictor of poor prognosis in cirrhotic patients with spontaneous bacterial peritonitis. J Clin Gastroenterol. 2014;48(5): Hsu SJ, Huang HC. Management of ascites in patients with liver cirrhosis: recent evidence and controversies. J Chin Med Assoc. 2013;76(3): Chang CS, Chen GH, Lien HC, Yeh HZ. Small intestine dysmotility and bacterial overgrowth in cirrhotic patients with spontaneous bacterial peritonitis. Hepatology. 1998;28(5): Deshpande A, Pasupuleti V, Thota P, et al. Acid-suppressive therapy is associated with spontaneous bacterial peritonitis in cirrhotic patients: a meta-analysis. J Gastroenterol Hepatol. 2013;28(2): Hoefs JC, Canawati HN, Sapico FL, Hopkins RR, Weiner J, Montgomerie JZ. Spontaneous bacterial peritonitis. Hepatology. 1982;2(4): Musskopf MI, Fonseca FP, Gass J, de Mattos AZ, John JA, de Mello Brandao AB. Prognostic factors associated with in-hospital mortality in patients with spontaneous bacterial peritonitis. Ann Hepatol. 2012;11(6):
6 136 Fatih Ensaroğlu et al/experimental and Clinical Transplantation (2015) Suppl 3: Exp Clin Transplant 14. Salerno F, Navickis RJ, Wilkes MM. Albumin infusion improves outcomes of patients with spontaneous bacterial peritonitis: a meta-analysis of randomized trials. Clin Gastroenterol Hepatol. 2013; 11(2): Sort P, Navasa M, Arroyo V, et al. Effect of intravenous albumin on renal impairment and mortality in patients with cirrhosis and spontaneous bacterial peritonitis. N Engl J Med. 1999;341(6): Fernandez J, Navasa M, Planas R, et al. Primary prophylaxis of spontaneous bacterial peritonitis delays hepatorenal syndrome and improves survival in cirrhosis. Gastroenterology. 2007;133(3):
Infections In Cirrhotic patients. Dr Abid Suddle Institute of Liver Studies King s College Hospital
Infections In Cirrhotic patients Dr Abid Suddle Institute of Liver Studies King s College Hospital Infection in cirrhotic patients Leading cause morbidity/mortality Common: 30-40% of hospitalised cirrhotic
More informationStudy of etiology, clinical profile and predictive factors of spontaneous bacterial peritonitis in cirrhosis of liver
International Journal of Research in Medical Sciences Kawale JB et al. Int J Res Med Sci. 2017 Jun;5(6):2326-2330 www.msjonline.org pissn 2320-6071 eissn 2320-6012 Original Research Article DOI: http://dx.doi.org/10.18203/2320-6012.ijrms20172096
More informationINCIDENCE OF BACTERIAL INFECTIONS IN CIRRHOSIS
INCIDENCE OF BACTERIAL INFECTIONS IN CIRRHOSIS Yoshida H et al (1993)* Deschenes M et al (1999)** Strauss E et al (1993) Borzio M et al (2002) PATIENTS 1140 140 170 405 INFECTIONS 15.4% 20% 47% 34% * Many
More informationRenal Dysfunction Is the Most Important Independent Predictor of Mortality in Cirrhotic Patients With Spontaneous Bacterial Peritonitis
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY 2011;9:260 265 Renal Dysfunction Is the Most Important Independent Predictor of Mortality in Cirrhotic Patients With Spontaneous Bacterial Peritonitis PUNEETA TANDON*,
More informationAscites Management. Atif Zaman, MD MPH Oregon Health & Science University Professor of Medicine Division of Gastroenterology and Hepatology
Ascites Management Atif Zaman, MD MPH Oregon Health & Science University Professor of Medicine Division of Gastroenterology and Hepatology Disclosure 1. The speaker Atif Zaman, MD MPH have no relevant
More informationThe Use of Albumin for the Prevention of Hepatorenal Syndrome in Patients with Spontaneous Bacterial Peritonitis and Cirrhosis
The Use of Albumin for the Prevention of Hepatorenal Syndrome in Patients with Spontaneous Bacterial Peritonitis and Cirrhosis http://www.funnyjunk.com/funny_pictures/1743659/enlarged/ Daniel Giddings,
More informationJMSCR Vol 05 Issue 11 Page November 2017
www.jmscr.igmpublication.org Impact Factor 5.84 Index Copernicus Value: 71.58 ISSN (e)-2347-176x ISSN (p) 2455-0450 DOI: https://dx.doi.org/10.18535/jmscr/v5i11.33 Prevalence of Hyponatremia among patients
More informationCirrhosis Complications
Cirrhosis Complications and Spontaneous Bacterial Peritonitis While these complications greatly increase mortality from decompensated cirrhosis, effective treatment is possible with early diagnosis. Vigilant
More informationHepatorenal Syndrome
Necker Seminars in Nephrology Institut Pasteur Paris, April 22, 2013 Hepatorenal Syndrome Dr. Richard Moreau 1 INSERM U773, Centre de Recherche Biomédicale Bichat-Beaujon CRB3, 2 Université Paris Diderot
More informationManagement of Cirrhosis Related Complications
Management of Cirrhosis Related Complications Ke-Qin Hu, MD, FAASLD Professor of Clinical Medicine Director of Hepatology University of California, Irvine Disclosure I have no disclosure related to this
More informationAdrenal Insufficiency in Patients with Liver Cirrhosis and Severe Sepsis: Effect on Survival after Treatment with Hydrocortisone ABSTRACT
20 Original Article Adrenal Insufficiency in Patients with Liver Cirrhosis and Severe Sepsis: Effect on Survival after Treatment with Hydrocortisone Pattanasirigool C Prasongsuksan C Settasin S Letrochawalit
More informationPREVENTION AND TREATMENT OF BACTERIAL INFECTIONS IN CIRRHOSIS
PREVENTION AND TREATMENT OF BACTERIAL INFECTIONS IN CIRRHOSIS Dr. J. Fernández. Head of the Liver Unit Hospital Clinic Barcelona, Spain AEEH Postgraduate Course, Madrid, February 15 2017 Prevalence of
More informationSystemic Inflammatory Response Syndrome and MELD Score in Hospital Outcome of Patients with Liver Cirrhosis
168 Original Article Systemic Inflammatory Response Syndrome and MELD Score in Hospital Outcome of Patients with Liver Cirrhosis Ramin Behroozian 1*, Mehrdad Bayazidchi 1, Javad Rasooli 1 1. Department
More informationTREBALL DE RECERCA. Facultat de Medicina Departament de Medicina Hospital de la Santa Creu i Sant Pau
TREBALL DE RECERCA INSUFICIÈNCIA RENAL I MORTALITAT DELS PACIENTS CIRRÒTICS AMB PERITONITIS BACTERIANA ESPOTÀNIA I BAIX RISC DE MORTALITAT NO TRACTATS AMB ALBÚMINA. Facultat de Medicina Departament de
More informationBeta-blockers in cirrhosis: Cons
Beta-blockers in cirrhosis: Cons Eric Trépo MD, PhD Dept. of Gastroenterology. Hepatopancreatology and Digestive Oncology. C.U.B. Hôpital Erasme. Université Libre de Bruxelles. Bruxelles. Belgium Laboratory
More informationJMSCR Vol 05 Issue 04 Page April 2017
www.jmscr.igmpublication.org Impact Factor 5.84 Index Copernicus Value: 83.27 ISSN (e)-2347-176x ISSN (p) 2455-0450 DOI: https://dx.doi.org/10.18535/jmscr/v5i4.202 A Study on Clinical and Laboratory Features
More informationCare of the Patient With Cirrhosis
REVIEW Care of the Patient With Cirrhosis Anitha Yadav, M.D., and Hugo E. Vargas, M.D. Caring for patients with cirrhosis involves multidisciplinary and timely management of several complications while
More informationAnaesthetic considerations and peri-operative risks in patients with liver disease
Anaesthetic considerations and peri-operative risks in patients with liver disease Dr. C. K. Pandey Professor & Head Department of Anaesthesiology & Critical Care Medicine Institute of Liver and Biliary
More informationClinical impact of healthcare-associated acquisition in cirrhotic patients with community-onset spontaneous bacterial peritonitis
ORIGINAL ARTICLE 2018 Mar 6. [Epub ahead of print] Clinical impact of healthcare-associated acquisition in cirrhotic patients with community-onset spontaneous bacterial peritonitis Jungok Kim 1, Cheol-In
More informationCauses of Liver Disease in US
Learning Objectives Updates in Outpatient Cirrhosis Management Jennifer Guy, MD MAS Director, Liver Cancer Program California Pacific Medical Center guyj@sutterhealth.org Review cirrhosis epidemiology,
More informationInitial approach to ascites
Ascites: Filling and Draining the Water Balloon Common Pathogenesis in Refractory Ascites, Hyponatremia, and Cirrhosis intrahepatic resistance sinusoidal portal hypertension Splanchnic vasodilation (effective
More informationEDUCATION PRACTICE. Management of Refractory Ascites. Clinical Scenario. The Problem
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY 2005;3:1187 1191 EDUCATION PRACTICE Management of Refractory Ascites ANDRÉS CÁRDENAS and PERE GINÈS Liver Unit, Institute of Digestive Diseases, Hospital Clínic,
More informationPrognostic factors associated with in-hospital mortality in patients with spontaneous bacterial peritonitis
ORIGINAL ARTICLE In-hospital mortality in patients with spontaneous bacterial peritonitis., 2012; 11 (6): 915-920 November-December, Vol. 11 No.6, 2012: 915-920 915 Prognostic factors associated with in-hospital
More informationThe Yellow Patient. Dr Chiradeep Raychaudhuri, Consultant Hepatologist, Hull University Teaching Hospitals NHS Trust
The Yellow Patient Dr Chiradeep Raychaudhuri, Consultant Hepatologist, Hull University Teaching Hospitals NHS Trust there s a yellow patient in bed 40. It s one of yours. Liver Cirrhosis Why.When.What.etc.
More informationManagement of Acute Decompensation of Cirrhosis JOHN O GRADY KING S COLLEGE HOSPITAL
Management of Acute Decompensation of Cirrhosis JOHN O GRADY KING S COLLEGE HOSPITAL Terminology Acute decompensation of cirrhosis - stable patient with sudden deterioration Acute-on-chronic liver failure
More informationCLINICAL How Should a Hospitalized Patient with Newly Diagnosed Cirrhosis Be Evaluated and Managed?
CLINICAL How Should a Hospitalized Patient with Newly Diagnosed Cirrhosis Be Evaluated and Managed? The Hospitalist. 2016 August;2016(8) Author(s): Raj Sehgal, MD; Joshua Hanson, MD, MPH; Division OF The
More informationManagement of Cirrhotic Complications Uncontrolled Ascites. Siwaporn Chainuvati, MD Siriraj Hospital Mahidol University
Management of Cirrhotic Complications Uncontrolled Ascites Siwaporn Chainuvati, MD Siriraj Hospital Mahidol University Topic Definition, pathogenesis Current therapeutic options Experimental treatments
More informationDiagnostic Value of Leucocyte Esterase Reagent Strip Test in Cirrhotic Patients with Ascites for Early Detection of Spontaneous Bacterial Peritonitis
Diagnostic Value of Leucocyte Esterase Reagent Strip Test in Cirrhotic Patients with Ascites for Early Detection of Spontaneous Bacterial Peritonitis Sunil Agrawal, Barjatya H.C. Introduction The word
More informationCIRCULATORY AND RENAL FAILURE IN CIRRHOSIS
CIRCULATORY AND RENAL FAILURE IN CIRRHOSIS Pere Ginès, MD Liver Unit, Hospital Clínic Barcelona, Catalunya, Spain CIRCULATORY AND RENAL FAILURE IN CIRRHOSIS Hecker R and Sherlock S, The Lancet 1956 RENAL
More informationBETA-BLOCKERS IN CIRRHOSIS.PRO.
BETA-BLOCKERS IN CIRRHOSIS.PRO. Angela Puente Sánchez. MD PhD Hepatology Unit. Gastroenterology department Marques de Valdecilla University Hospital. Santander INTRODUCTION. Natural history of cirrhosis
More informationEvaluating HIV Patient for Liver Transplantation. Marion G. Peters, MD Professor of Medicine University of California San Francisco USA
Evaluating HIV Patient for Liver Transplantation Marion G. Peters, MD Professor of Medicine University of California San Francisco USA Slide 2 ESLD and HIV Liver disease has become a major cause of death
More informationHepatorenal syndrome. Jan T. Kielstein Departent of Nephrology Medical School Hannover
Hepatorenal syndrome Jan T. Kielstein Departent of Nephrology Medical School Hannover Hepatorenal Syndrome 1) History of HRS 2) Pathophysiology of HRS 3) Definition of HRS 4) Clinical presentation of HRS
More informationComplications Requiring Hospital Admission and Causes of In-Hospital Death over Time in Alcoholic and Nonalcoholic Cirrhosis Patients
Gut and Liver, Vol. 10, No. 1, January 2016, pp. 95-100 ORiginal Article Complications Requiring Hospital Admission and Causes of In-Hospital Death over Time in and Cirrhosis Patients Hee Yeon Kim, Chang
More informationSeverity and Mortality Prediction in Chronic Liver Disease using Child PUGH and MELD scales
International Journal of Advanced Biotechnology and Research (IJABR) ISSN 0976-2612, Online ISSN 2278 599X, Vol-10, Issue-1, 2019, pp519-524 http://www.bipublication.com Research Article Severity and Mortality
More informationManagement of Ascites and Hepatorenal Syndrome. Florence Wong University of Toronto. June 4, /16/ Gore & Associates: Consultancy
Management of Ascites and Hepatorenal Syndrome Florence Wong University of Toronto June 4, 2016 6/16/2016 1 Disclosures Gore & Associates: Consultancy Sequana Medical: Research Funding Mallinckrodt Pharmaceutical:
More informationFilippo Schepis, MD Università degli Studi di Modena e Reggio Emilia
Filippo Schepis, MD Università degli Studi di Modena e Reggio Emilia Il sottoscritto dichiara di non aver avuto/di aver avuto negli ultimi 12 mesi conflitto d interesse in relazione a questa presentazione
More informationHepatorenal syndrome a defined entity with a standard treatment?
Hepatorenal syndrome a defined entity with a standard treatment? Falk Symposium 162 Dresden - October 14, 2007 Alexander L. Gerbes Klinikum of the University of Munich Grosshadern Department of Medicine
More informationJOURNAL PRESENTATION. Dr Tina Fan Tseung Kwan O Hospital 17 th Jan 2013
JOURNAL PRESENTATION Dr Tina Fan Tseung Kwan O Hospital 17 th Jan 2013 THE COMBINATION OF OCTREOTIDE AND MIDODRINE IS NOT SUPERIOR TO ALBUMIN IN PREVENTING RECURRENCE OF ASCITES AFTER LARGE-VOLUME PARACENTESIS
More informationOptimal management of ascites
Optimal management of ascites P. Angeli, Dept. of Medicine, Unit of Internal Medicine and epatology (), University of Padova (Italy) pangeli@unipd.it 10th Paris epatology Conference National Conference
More informationLiver Transplantation: The End of the Road in Chronic Hepatitis C Infection
University of Massachusetts Medical School escholarship@umms UMass Center for Clinical and Translational Science Research Retreat 2012 UMass Center for Clinical and Translational Science Research Retreat
More informationUpdate in abdominal Surgery in cirrhotic patients
Update in abdominal Surgery in cirrhotic patients Safi Dokmak HBP department and liver transplantation Beaujon Hospital, Clichy, France Cairo, 5 April 2016 Cirrhosis Prevalence in France (1%)* Patients
More informationEASL clinical practice guidelines on the management of ascites, spontaneous bacterial peritonitis, and hepatorenal syndrome in cirrhosis
EASL clinical practice guidelines on the management of ascites, spontaneous bacterial peritonitis, and hepatorenal syndrome in cirrhosis European Association for the Study of the Liver 1 Ascites is the
More informationDiagnosis of Spontaneous Bacterial Peritonitis by Identification of 16s rrna Genes in Liver Cirrhosis Patients
Med. J. Cairo Univ., Vol. 83, No. 2, December: 209-214, 2015 www.medicaljournalofcairouniversity.net Diagnosis of Spontaneous Bacterial Peritonitis by Identification of 16s rrna Genes in Liver Cirrhosis
More informationEsophageal Varices Beta-Blockers or Band Ligation. Cesar Yaghi MD Hotel-Dieu de France University Hospital Universite Saint Joseph
Esophageal Varices Beta-Blockers or Band Ligation Cesar Yaghi MD Hotel-Dieu de France University Hospital Universite Saint Joseph Esophageal Varices Beta-Blockers or Band Ligation? Risk of esophageal variceal
More informationNorepinephrine versus Terlipressin for the Treatment of Hepatorenal Syndrome
Norepinephrine versus Terlipressin for the Treatment of Hepatorenal Syndrome Disclosure I have no conflicts of interest to disclose Name: Margarita Taburyanskaya Title: PharmD, PGY1 Pharmacy Practice Resident
More informationCase Report: Acute-on-Chronic Liver Failure: Making the Diagnosis between Infection and Acute Alcoholic Hepatitis
Diagnostic Problems in Hepatology 181 Case Report: Acute-on-Chronic Liver Failure: Making the Diagnosis between Infection and Acute Alcoholic Hepatitis Carmen Sendra, MD 1 Javier Ampuero, MD, PhD 1,2 Álvaro
More informationOnline Supplement for:
Online Supplement for: INFLUENCE OF COMBINED INTRAVENOUS AND TOPICAL ANTIBIOTIC PROPHYLAXIS ON THE INCIDENCE OF INFECTIONS, ORGAN DYSFUNCTIONS, AND MORTALITY IN CRITICALLY ILL SURGICAL PATIENTS A PROSPECTIVE,
More informationStudy On Ascitic Fluid Complement3 Level In Cirrhotic Patients With Spontaneous Bacterial Peritonitis And Without Spontaneous Bacterial Peritonitis
ISPUB.COM The Internet Journal of Gastroenterology Volume 6 Number 1 Study On Ascitic Fluid Complement3 Level In Cirrhotic Patients With Spontaneous Bacterial Peritonitis And Without Spontaneous Bacterial
More informationCirrhosis is an important cause of morbidity and mortality
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY 2009;7:487 493 Role of Fluoroquinolones in the Primary Prophylaxis of Spontaneous Bacterial Peritonitis: Meta-Analysis ROHIT LOOMBA,* ROBERT WESLEY, ANDREW BAIN,*
More informationAnalysis of Risk Factors for Patients with Liver Cirrhosis Complicated with Spontaneous Bacterial Peritonitis
Iran J Public Health, Vol. 47, No.12, Dec 2018, pp.1883-1890 Original Article Analysis of Risk Factors for Patients with Liver Cirrhosis Complicated with Spontaneous Bacterial Peritonitis Yuan WANG, *Qingyu
More informationManagement of Chronic Liver Failure/Cirrhosis Complications in Hospitals. By: Dr. Kevin Dolehide
Management of Chronic Liver Failure/Cirrhosis Complications in Hospitals By: Dr. Kevin Dolehide Overview DX Cirrhosis and Prognosis Compensated Decompensated Complications Of Cirrhosis Management Of Complications
More informationKing Abdul-Aziz University Hospital (KAUH) is a tertiary
Modelling Factors Causing Mortality in Oesophageal Varices Patients in King Abdul Aziz University Hospital Sami Bahlas Abstract Objectives: The objective of this study is to reach a model defining factors
More informationHepatology on the AMU
Hepatology on the AMU RCP day, 8 th February 2018 Jo Leithead Consultant in Hepatology and Liver Transplantation Addenbrookes Hospital Cambridge Is liver disease relevant to me? Williams R, Lancet 2014
More informationCirrhosis and Portal Hypertension Gastroenterology Teaching Project American Gastroenterological Association
CIRRHOSIS AND PORTAL HYPERTENSION Cirrhosis and Portal Hypertension Gastroenterology Teaching Project American Gastroenterological Association WHAT IS CIRRHOSIS? What is Cirrhosis? DEFINITION OF CIRRHOSIS
More informationASCITES. Dr KS Cheung Queen Mary Hospital
ASCITES Dr KS Cheung Queen Mary Hospital Outline Pathophysiology Differential diagnosis of ascites Diagnostic paracentesis Ascitic fluid analysis Management of Ascites Management of spontaneous bacterial
More informationDISCLOSURES. This activity is jointly provided by Northwest Portland Area Indian Health Board and Cardea
DISCLOSURES This activity is jointly provided by Northwest Portland Area Indian Health Board and Cardea Cardea Services is approved as a provider of continuing nursing education by Montana Nurses Association,
More informationAscites is the most common complication of cirrhosis and. Natural History of Patients Hospitalized for Management of Cirrhotic Ascites
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY 2006;4:1385 1394 Natural History of Patients Hospitalized for Management of Cirrhotic Ascites RAMON PLANAS,* SILVIA MONTOLIU,* BELEN BALLESTÉ, MONICA RIVERA, MIREIA
More informationCorresponding Author: Dr. Ali Saqib, Department of Medicine, Madina Teaching Hospital, Faisalabad.
Original Article FREQUENCY OF SPONTANEOUS BACTERIAL PERITONITIS (SBP) IN CIRRHOTIC PATIENTS WITH ASCITES DUE TO HEPATITIS B AND C Ali Saqib 1, Rizwan Rasul Khan 2, Zahid Masood 3, Irshad ul Haque 4 1 Assistant
More informationCIRRHOSIS Definition
Cirrhosis Update Robert S. Brown, Jr., MD, MPH Vice Chair, Transitions of Care Interim Chief, Division of Gastroenterology & Hepatology Weill Cornell Medical College CIRRHOSIS Definition Irreversible fibrous
More informationOriginal Article PLATELET COUNT TO SPLEEN DIAMETER RATIO AS A PREDICTOR OF ESOPHAGEAL VARICES IN PATIENTS OF LIVER CIRRHOSIS DUE TO HEPATITIS C VIRUS
Original Article AS A PREDICTOR OF ESOPHAGEAL VARICES IN PATIENTS OF LIVER CIRRHOSIS DUE TO HEPATITIS C VIRUS Khalid Amin 1, Dilshad Muhammad 2, Amin Anjum 3, Kashif Jamil 4, Ali Hassan 5 1 Associate Professor
More informationPACT module Acute hepatic failure. Intensive Care Training Program Radboud University Medical Centre Nijmegen
PACT module Acute hepatic failure Intensive Care Training Program Radboud University Medical Centre Nijmegen Acute Liver Failure Acute on Chronic Liver Failure Acute loss of hepatocellular function in
More informationSetting The setting was secondary care. The economic study was carried out in Turkey.
Oral ciprofloxacin versus intravenous cefotaxime and ceftriaxone in the treatment of spontaneous bacterial peritonitis Tuncer I, Topcu N, Durmus A, Turkdogan M K Record Status This is a critical abstract
More informationEfficacy and Safety of Thymoglobulin and Basiliximab in Kidney Transplant Patients at High Risk for Acute Rejection and Delayed Graft Function
ArtIcle Efficacy and Safety of Thymoglobulin and Basiliximab in Kidney Transplant Patients at High Risk for Acute Rejection and Delayed Graft Function Guodong Chen, 1 Jingli Gu, 2 Jiang Qiu, 1 Changxi
More informationKing s College Hospital NHS Foundation Trust. Acute on Chronic Liver Failure: Practical management outside the tertiary centre.
King s College Hospital NHS Foundation Trust NHS Acute on Chronic Liver Failure: Practical management outside the tertiary centre. William Bernal Professor of Liver Critical Care Liver Intensive Therapy
More informationCLIF Consortium. Protocol of the CLIF Acute-oN-ChrONic LIver Failure in Cirrhosis (CANONIC) Core Study
CLIF Consortium Protocol of the CLIF Acute-oN-ChrONic LIver Failure in Cirrhosis (CANONIC) Core Study Case Report Form (Final) Center: Investigator: Investigator s Signature: The highlighted information
More informationABSTRACT PURPOSE METHODS
ABSTRACT PURPOSE The purpose of this study was to characterize the CDI population at this institution according to known risk factors and to examine the effect of appropriate evidence-based treatment selection
More informationThe Management of Ascites & Hepatorenal Syndrome. Florence Wong University of Toronto. Falk Symposium March 14, 2008
The Management of Ascites & Hepatorenal Syndrome Florence Wong University of Toronto Falk Symposium March 14, 2008 Management of Ascites Sodium Restriction Mandatory at all stages of ascites in order to
More informationEtiology of liver cirrhosis
Liver cirrhosis 1 Liver cirrhosis Liver cirrhosis is the progressive replacement of normal hepatic cells by fibrous scar tissue, This scarring is accompanied by the loss of viable hepatocytes, which are
More informationKDIGO (Kidney Disease: Improving Global Outcomes) criteria as a predictor of hospital mortality in cirrhotic patients
KDIGO (Kidney Disease: Improving Global Outcomes) criteria as a predictor of hospital mortality in cirrhotic patients LIVER Murat Bıyık 1, Hüseyin Ataseven 1, Zeynep Bıyık 2, Mehmet Asil 1, Sami Çifçi
More informationB C Outlines. Child-Pugh scores
B C 2016-12-09 Outlines Child-Pugh scores CT MRI Fibroscan / ARFI Histologic Scoring Systems for Fibrosis Fibrosis METAVIR Ishak None 0 0 Portal fibrosis (some) 1 1 Portal fibrosis (most) 1 2 Bridging
More informationHEPATOrenal Syndrome Type I: Correct Diagnosis = Correct Management
HEPATOrenal Syndrome Type I: Correct Diagnosis = Correct Management Stephen G. M. Wong BSc, BSc(Med), MD, MHSc, FRCPC Associate Professor of Medicine Director, Hepatology Education Section of Hepatology
More informationPACT module Acute hepatic failure. Intensive Care Training Program Radboud University Medical Centre Nijmegen
PACT module Acute hepatic failure Intensive Care Training Program Radboud University Medical Centre Nijmegen Acute Liver Failure Acute on Chronic Liver Failure Acute loss of hepatocellular function in
More informationIntron A Hepatitis C. Intron A (interferon alfa-2b) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.01.05 Subject: Intron A Hepatitis C Page: 1 of 5 Last Review Date: November 30, 2018 Intron A Hepatitis
More informationREVIEW. Ariel W. Aday, M.D.,* Nicole E. Rich, M.D.,* Arjmand R. Mufti, M.D., and Shannan R. Tujios, M.D.
REVIEW CON ( The Window Is Closed ): In Patients With Cirrhosis With Ascites, the Clinical Risks of Nonselective beta-blocker Outweigh the Benefits and Should NOT Be Prescribed Ariel W. Aday, M.D.,* Nicole
More informationComplications of Cirrhosis
Complications of Cirrhosis Causes of Cirrhosis Alcohol Chronic Viral Hepatitis (B/C) Haemochromatosis Autoimmune Hepatitis NAFLD/NASH Primary Biliary Cirrhosis Primary Sclerosing Cholangitis 1-AT deficiency
More informationProgram Disclosure. This program is supported by an educational grant from Salix Pharmaceuticals.
Program Disclosure This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through the sponsorship
More informationNational liver offering scheme
1 National liver offering scheme Outline 1 Hub Specialist Nurse Organ Donation (SNOD) registers donor with Operations 2 matching Hub Operations initiates the run 3 Hub Matching run offering list printed
More informationACUTE-ON-CHRONIC LIVER FAILURE: DEFINITION, DIAGNOSIS AND CLINICAL CHARACTERISTICS.
ACUTE-ON-CHRONIC LIVER FAILURE: DEFINITION, DIAGNOSIS AND CLINICAL CHARACTERISTICS. Vicente Arroyo 1, 2, Rajiv Jalan 2, 3 1 Institut de Investigacions Biomèdiques August Pi I Sunyer. University of Barcelona.
More informationOn-Call Upper GI Bleeding. Upper Gastrointestinal Bleeding
On-Call Upper GI Bleeding John R Saltzman MD, FACG Director of Endoscopy Brigham and Women s Hospital Associate Professor of Medicine Harvard Medical School Upper Gastrointestinal Bleeding 300,000000 hospitalizations/year
More informationStudy of bacteriological profile in spontaneous bacterial peritonitis in cirrhotic patients at a tertiary teaching hospital in Northern India
INTERNATIONAL JOURNAL OF CURRENT RESEARCH IN BIOLOGY AND MEDICINE ISSN: 2455-944X www.darshanpublishers.com DOI:10.22192/ijcrbm Volume 3, Issue 3-2018 Original Research Article Study of bacteriological
More informationHepatorenal syndrome. Jan Jan T. T. Kielstein Departent of of Nephrology Medical School School Hannover
Hepatorenal syndrome Jan Jan T. T. Kielstein Departent of of Nephrology Medical School School Hannover Hepatorenal Syndrome 1) History of HRS 2) Pathophysiology of HRS 3) Definition of HRS 4) Clinical
More informationAntimicrobial prophylaxis in liver transplant A multicenter survey endorsed by the European Liver and Intestine Transplant Association
Antimicrobial prophylaxis in liver transplant A multicenter survey endorsed by the European Liver and Intestine Transplant Association Els Vandecasteele, Jan De Waele, Dominique Vandijck, Stijn Blot, Dirk
More informationManaging Cirrhosis. Cirrhosis of the liver is a progressive, fibrosing. Ascites. By Cameron Ghent, MD, FRCPC. Complications of Cirrhosis
Focus on CME at the University of Western Ontario Managing Cirrhosis By Cameron Ghent, MD, FRCPC Cirrhosis of the liver is a progressive, fibrosing process resulting in nodule formation and microvascular
More informationCONTROLLED DOCUMENT. Cirrhosis Care Bundle CATEGORY: Clinical Guidelines. CLASSIFICATION: Clinical. Controlled Document CG201 Number:
Cirrhosis Care Bundle CONTROLLED DOCUMENT CATEGORY: Clinical Guidelines CLASSIFICATION: Clinical Controlled Document CG201 Number: Version Number: 1 Controlled Document Clinical Guidelines Group Sponsor:
More informationAmmonia level at admission predicts in-hospital mortality for patients with alcoholic hepatitis
Gastroenterology Report, 5(3), 2017, 232 236 doi: 10.1093/gastro/gow010 Advance Access Publication Date: 1 May 2016 Original article ORIGINAL ARTICLE Ammonia level at admission predicts in-hospital mortality
More informationTitle: CLIF-C ACLF score is a better mortality. patients with Acute on Chronic Liver Failure admitted to the ward
Title: CLIF-C ACLF score is a better mortality predictor than MELD, MELD-Na and CTP in patients with Acute on Chronic Liver Failure admitted to the ward Authors: Rita Barosa, Lídia Roque Ramos, Marta Patita,
More informationHealthy Liver Cirrhosis
Gioacchino Angarano Clinica delle Malattie Infettive Università degli Studi di Foggia Healthy Liver Cirrhosis Storia naturale dell epatite HCVcorrelata in assenza di terapia Paestum 13-15 Maggio 24 The
More informationLaura Mazer 1, Elliot B. Tapper 2, Gail Piatkowski 2, Michelle Lai 3
RESEARCH ARTICLE Dosing of ceftriaxone and outcomes after spontaneous bacterial peritonitis [version 1; referees: 3 approved with reservations] Laura Mazer 1, Elliot B. Tapper 2, Gail Piatkowski 2, Michelle
More informationThe Association Between the Serum Sodium Level and the Severity of Complications in Liver Cirrhosis
ORIGINAL ARTICLE DOI: 10.3904/kjim.2009.24.2.106 The Association Between the Serum Sodium Level and the Severity of Complications in Liver Cirrhosis Jong Hoon Kim, June Sung Lee, Seuk Hyun Lee, Won Ki
More informationT herapeutic (that is, total) paracentesis is used in patients
90 LIVER AND BILIARY DISEASE Comparison of the effect of terlipressin and albumin on arterial blood volume in patients with cirrhosis and tense ascites treated by : a randomised pilot study R Moreau, T
More informationAssessment of Liver Function: Implications for HCC Treatment
Assessment of Liver Function: Implications for HCC Treatment A/P Dan Yock Young MBBS, PhD, MRCP, MMed. FAMS Chair, University Medicine Cluster. NUHS Head, Department of Medicine, National University of
More informationDoes Viral Cure Prevent HCC Development
Does Viral Cure Prevent HCC Development Prof. Henry LY Chan Head, Division of Gastroenterology and Hepatology Director, Institute of Digestive Disease Director, Center for Liver Health Assistant Dean,
More informationCHAPTER 7. End Stage Liver Disease in the ICU: Walking a Tightrope. Lynn A. Kelso, MSN, APRN, FCCM, FAANP University of Kentucky College of Nursing
CHAPTER 7 End Stage Liver Disease in the ICU: Walking a Tightrope Lynn A. Kelso, MSN, APRN, FCCM, FAANP University of Kentucky College of Nursing Besey Oren, Assistant Professor Istanbul University Health
More informationAre we adequately screening at-risk patients for hepatocellular carcinoma in the outpatient setting?
Rajani Sharma, PGY1 Geriatrics CRC Project, 12/19/13 Are we adequately screening at-risk patients for hepatocellular carcinoma in the outpatient setting? A. Study Purpose and Rationale Hepatocellular carcinoma
More informationHepatitis C: How sick can we treat? Robert S. Brown, Jr., MD, MPH Vice Chair, Transitions of Care Interim Chief, Division of
Hepatitis C: How sick can we treat? Robert S. Brown, Jr., MD, MPH Vice Chair, Transitions of Care Interim Chief, Division of Gastroenterology & Hepatology www.livermd.org HCV in advanced disease In principle
More informationViral Hepatitis The Preventive Potential of Antiviral Therapy. Thomas Berg
Viral Hepatitis The Preventive Potential of Antiviral Therapy Thomas Berg Therapeutic and preventive strategies in patients with hepatitis virus infection Treatment of acute infection Treatment of chronic
More informationLife After SVR for Cirrhotic HCV
Life After SVR for Cirrhotic HCV KIM NEWNHAM MN, NP CIRRHOSIS CARE CLINIC UNIVERSITY OF ALBERTA Objectives To review the benefits of HCV clearance in cirrhotic patients To review some of the emerging data
More informationDenver Shunts vs TIPS for Ascites
Denver Shunts vs TIPS for Ascites Hooman Yarmohammadi MD Assistant Professor of Radiology Interventional Radiology & Image Guided Therapies Memorial Sloan-Kettering Cancer Center, New York, USA Hooman
More informationIndex. Note: Page numbers of article titles are in boldface type.
Index Note: Page numbers of article titles are in boldface type. A Accelerated intravascular coagulation and fibrinolysis (AICF) in liver disease, 390 391 Acid suppression in liver disease, 403 404 ACLF.
More informationGI bleeding in chronic liver disease
GI bleeding in chronic liver disease Stuart McPherson Consultant Hepatologist Liver Unit, Freeman Hospital, Newcastle upon Tyne and Institute of Cellular Medicine, Newcastle University. Case 54 year old
More information